Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096308 | 1.00 | FLT3 (0.51) | FLT3ERBB2EGFRKDRTNK2 | |
| SCHEMBL1105319 | 0.85 | FLT3 (0.56) | FLT3ERBB2EGFRKDRTNK2 | |
| SCHEMBL1094553 | 0.85 | FLT3 (0.56) | FLT3ERBB2EGFRKDRTNK2 | |
| SCHEMBL31466883 | 0.81 | EGFR (0.71) | ERBB2EGFRAURKA | |
| SCHEMBL30362981 | 0.81 | EGFR (0.71) | ERBB2EGFRAURKA | |
| SCHEMBL4736323 | 0.81 | EGFR (0.71) | ERBB2EGFRAURKA | |
| SCHEMBL1105316 | 0.81 | EGFR (0.71) | ERBB2EGFRAURKA | |
| SCHEMBL14162283 | 0.81 | ERBB2 (0.63) | FLT3ERBB2EGFRKDRMET | |
| SCHEMBL1095083 | 0.81 | EGFR (0.64) | FLT3ERBB2EGFRKDRTNK2 | |
| SCHEMBL1095081 | 0.81 | EGFR (0.64) | FLT3ERBB2EGFRKDRTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8278446-B2 | reacting 4-amino-6-chloro-pyrimidine-5-carbaldehyde with 4-benzyloxy-3-chloro-phenylamine in an aqueous solvent and a catalytic amount of hydrochloric acid, to providw 4-amino-6-(4-benzyloxy-3-chloro-phenylamino)-pyrimidine-5-carbaldehyde, then oximination with (2-morpholin-4-yl-ethyl)-hydroxylamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | disclosed |
| WO-2007081630-A2 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | MAP3K2, MAP3K1, MAP3K20 | FLT3 101/4885ERBB2 124/4885EGFR 1201/4885 |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | MAP3K2, MAP3K1, MAP3K20 | FLT3 101/4885ERBB2 124/4885EGFR 1201/4885 |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | DHPS, DPYD, DCPS | FLT3 140/4885ERBB2 301/4885EGFR 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.